Chengdu Olin Biotechnology

Chengdu Olin Biological Technology is a China-based biopharmaceutical company specializing in the research, development, production, and commercialization of human vaccines. The company's product portfolio is anchored by its Adsorbed Tetanus Vaccine, which holds a significant market share in China, alongside other commercialized products like the Hib and AC conjugate vaccines. Olin Biological is notably advancing a robust pipeline of innovative candidates, including a world-first Recombinant Staphylococcus Aureus Vaccine currently in Phase 3 clinical trials. Utilizing advanced technology platforms for recombinant proteins and polysaccharide-protein conjugation, the company focuses on addressing critical unmet needs in infectious disease prevention. Headquartered in Chengdu, Olin Biological is listed on the Shanghai Stock Exchange's STAR Market and operates large-scale GMP-compliant manufacturing facilities.